Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
This study aims to investigate the connection between 25-hydroxyvitamin D (25(OH)D) levels and the prognosis of breast cancer with various estrogen receptor (ER) statuses.
Source: Abstract. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Genetic instrumental-variable study.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER− breast cancer: A Mendelian randomization study
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER− breast cancer: A Mendelian randomization study
Genetic instrumental-variable study · Medicine · 2024
Original publication title
Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER− breast cancer: A Mendelian randomization study
Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
This study aims to investigate the connection between 25-hydroxyvitamin D (25(OH)D) levels and the prognosis of breast cancer with various estrogen receptor (ER) statuses. The summary statistics of 25(OH)D levels was obtained from a GWAS of 441,291 individuals and the information of breast cancer was collected from the Breast Cancer Association Consortium. We analyzed the causal association between 25(OH)D levels and breast cancer prognosis using a number of approaches, including inverse variance weighting (IVW). The heterogeneity test was performed using Cochran Q test.
IVW, Mendelian randomization (MR)-Egger, and MR Pleiotropy RESidual Sum and Outlier methods were used for sensitivity analysis. In addition, a multivariate MR adjusted for total triglycerides, total cholesterol, and body mass index was used for further analysis. Two-sample MR results showed that 25(OH)D levels were not associated with prognosis in overall breast cancer (odds ratio [OR] = 0.93, 95% confidence interval [CI] = 0.73 to 1.19, IVW exam) and estrogen receptor positive (ER+) breast cancers (OR = 1.12, 95% CI = 0.77 to 1.63, IVW exam) and were protective associated with prognosis in estrogen receptor negative (ER−) breast cancers (OR = 0.55, 95% CI = 0.34 to 0.87, IVW exam).
Sensitivity analysis did not observe the presence of heterogeneity and horizontal pleiotropy. In multivariate MR analysis, after adjusting for total triglycerides, total cholesterol, and body mass index, the correlation between the protective relationship between 25(OH)D levels and the prognosis for ER− breast cancer remained and became increasingly significant (OR = 0.51, 95% CI = 0.31 to 0.83, P = .007). This study demonstrated a protective relationship between 25(OH)D levels and the prognosis of ER− breast cancer, but there was no connection between 25(OH)D levels and the prognosis of ER+ breast cancer.
Authors’ abstract
This study aims to investigate the connection between 25-hydroxyvitamin D (25(OH)D) levels and the prognosis of breast cancer with various estrogen receptor (ER) statuses. The summary statistics of 25(OH)D levels was obtained from a GWAS of 441,291 individuals and the information of breast cancer was collected from the Breast Cancer Association Consortium. We analyzed the causal association between 25(OH)D levels and breast cancer prognosis using a number of approaches, including inverse variance weighting (IVW). The heterogeneity test was performed using Cochran Q test.
IVW, Mendelian randomization (MR)-Egger, and MR Pleiotropy RESidual Sum and Outlier methods were used for sensitivity analysis. In addition, a multivariate MR adjusted for total triglycerides, total cholesterol, and body mass index was used for further analysis. Two-sample MR results showed that 25(OH)D levels were not associated with prognosis in overall breast cancer (odds ratio [OR] = 0.93, 95% confidence interval [CI] = 0.73 to 1.19, IVW exam) and estrogen receptor positive (ER+) breast cancers (OR = 1.12, 95% CI = 0.77 to 1.63, IVW exam) and were protective associated with prognosis in estrogen receptor negative (ER−) breast cancers (OR = 0.55, 95% CI = 0.34 to 0.87, IVW exam).
Sensitivity analysis did not observe the presence of heterogeneity and horizontal pleiotropy. In multivariate MR analysis, after adjusting for total triglycerides, total cholesterol, and body mass index, the correlation between the protective relationship between 25(OH)D levels and the prognosis for ER− breast cancer remained and became increasingly significant (OR = 0.51, 95% CI = 0.31 to 0.83, P = .007). This study demonstrated a protective relationship between 25(OH)D levels and the prognosis of ER− breast cancer, but there was no connection between 25(OH)D levels and the prognosis of ER+ breast cancer.
Publication and source details
Original title: Genetic evidence supporting the causal role of 25-hydroxyvitamin D levels in the prognosis of ER− breast cancer: A Mendelian randomization study
Shang Wu; Xin-Di Ma; Xiang-Mei Zhang; Chao Shi; Kai-Ye Du; Yun-Jiang Liu
Medicine · 2024
* Correspondence: Yun-Jiang Liu, Breast Center, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China (e-mail: lyj818326@hebmu.edu.cn).Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.2024https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T03:26:34.091105+00:00
DOI: 10.1097/md.0000000000040262 · PMC11521050